RADICAL PC
14 Dec 2022
Trial Summary
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Acronym:
RADICAL PC
ACTRN/NCT /ethics:
NCT03127631
Scientific title:
The Role of Androgen Deprivation Therapy In Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Sponsor / Cooperative group:
McMaster University
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | - |
| Age Range | 45 Years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2015-10-21 |
| Anticipated End Date | 2025-12-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Braden Higgs |
| Recruitment Status | Recruiting |